Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Shanthi N. Pal"'
Autor:
Watcharee Rungapiromnan, Mengistab Teferi, Viola Macolić Šarinić, Pattreya Pokhagul, Diego Macías Saint-Gerons, Lilit Ghazaryan, Jose Luis Castro, Madhur Gupta, Asnakech Alemu, Shanthi N. Pal, Gayane Ghukasyan, Porntip Jiamsuchon, Noha Iessa, Naira Romanova
Publikováno v:
Drug Safety
Introduction The Smart Safety Surveillance (3S) concept is based on the understanding that, when faced with competing pharmacovigilance priorities, countries will have to invest judiciously, by focusing on new priority products, sharing work and reso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b9ff68d45b90e0bf2bb8d92d9cde9c
https://pubmed.ncbi.nlm.nih.gov/34331675
https://pubmed.ncbi.nlm.nih.gov/34331675
Publikováno v:
Bulletin of the World Health Organization, Vol 92, Iss 12, Pp 918-919 (2014)
Externí odkaz:
https://doaj.org/article/135cc0808a99496b8632bfd2bdda0285
Autor:
Rhosyn Tuta, Houda Sefiani, Mariama Sire Sano, Jean Louis NdDiaye, Diakalidia Kone, Maddy Marasciulo, Paul Snell, Matthew Cairns, Lantorina Razafindralambo, Rahila Abdoulaye, Sonny Johnbull Ogboi, Kovana Marcel Loua, Momodou Kalleh, Julian Muwanguzi, Ibrahim Laminou, Rebecca F. Grais, Tony Eloike, Serign J. Ceesay, Aishatu Yinusa Cassandra Elagbaje, Harriet Kivumbi, Kalifa Bojang, Alice Kiba, Issaka Zongo, Halimatou Alassana Messan, Ebenezer Baba, Rachida Souleymani, Moussa Keita, Ibrahim Ouba, Susana Scott, Nadine Ngarnaye, Matt Coldiron, Yacine Djibo, Abdoulaye Djimde, Gladys Tetteh, Hadiza Jackou, Djiddi Ali Sougoudi, George Jagoe, Abdoulaye Hama Diallo, Kolawole Maxwell, Daugla Doumagoum, Issaka Sagara, Eric Hubbard, Hamit Kesseley, Emile Ouedraogo, André-Marie Tchouatieu, Musa Abubakar Kana, Khalid B. Beshir, Godwin Ntadom, Fatou Jah, Eugene Kaman Lama, Alassane Dicko, Colin J. Sutherland, Jean-Bosco Ouédraogo, Shanthi N. Pal, Markieu Janneh Kaira, Fara Ndiaye, Corinne Merle, Prudence Hamade, Kodbesse Boulotigam, James K Tibenderana, Timothee Guilavogui, Sham Lal, Noha Iessa, Paul Milligan, Jane Achan, Yolanda Fernandez, Raoul Mansukhani, Suzanne Van Hulle, Huja Jah, Colin Gilmartin, Arantxa Roca-Feltrer, Mamadou Chérif Traore, Bala Audu, Diego Moroso, David Collins, Joanna Stenstrom Johansson, Yacouba Savodogo, Balla Kandeh, Christine M Halleux, Adama Sanogo, Patrice Coulibaly
Publikováno v:
Lancet (London, England)
Summary Background Seasonal malaria chemoprevention (SMC) aims to prevent malaria in children during the high malaria transmission season. The Achieving Catalytic Expansion of SMC in the Sahel (ACCESS-SMC) project sought to remove barriers to the sca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fd023d3a0d31a2fd7843cf9a39093fd
https://pubmed.ncbi.nlm.nih.gov/33278921
https://pubmed.ncbi.nlm.nih.gov/33278921
Autor:
George Sabblah, Edward Abwao, Shanthi N. Pal, Adeline Osakwe, Alexander N. O. Dodoo, Jayesh Pandit, George Muthuri, Star Khoza, Priscilla P. Nyambayo, Mimi Darko, Cassandra Elagbaje, Comfort Kunak Suku, Geraldine Hill
Publikováno v:
Drug Safety
Introduction Cohort event monitoring (CEM) is an intensive method of post-marketing surveillance for medicines safety. The method is based on prescription event monitoring, which began in the 1970s, and has since been adapted by WHO for monitoring th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::165e5757182da1d98865a6814d125185
https://doi.org/10.1007/s40264-015-0331-7
https://doi.org/10.1007/s40264-015-0331-7
Publikováno v:
Drug Safety
The Monitoring Medicines project (MM), funded by the FP-7 EU framework, was carried out between 2009 and 2013 by a consortium of 11 partners. The objectives were to support and strengthen consumer reporting of adverse drug reactions (ADRs); expand th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ece6ea58088d2e87dbcc2498cbc8b06
http://europepmc.org/articles/PMC4544540
http://europepmc.org/articles/PMC4544540
Autor:
Rachida Soulaymani-Bencheikh, Ian W. Boyd, John McEwen, I. Ralph Edwards, Ian C. K. Wong, Kenneth Hartigan-Go, Jürgen Beckmann, Claudia Vaca, Priya Bahri, Marie Lindquist, Gerald J. Dal Pan, Shanthi N. Pal, Marco Tuccori, Brian Edwards, Yola Moride, Andrew Bate, Ulrich Hagemann, Sten Olsson
Publikováno v:
Drug Safety. 37:743-759
The importance of pharmacovigilance (PV) for safe medicines and their safe use has increasingly been recognised during the last few years [1]. PV has been subject of intense research and regulation. In particular, it has earned more and more importan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f96b1c90349fa979af7515861b189a79
https://doi.org/10.1007/s40264-014-0216-1
https://doi.org/10.1007/s40264-014-0216-1
Publikováno v:
Drug Safety; Vol 35
Drug Safety, 35(1), 45-60. ADIS INT LTD
Drug Safety, 35(1), 45-60. ADIS INT LTD
Background: Patients are important stakeholders in pharmacovigilance; however, little formal evaluation has been undertaken of existing patient reporting schemes within and outside Europe. If patient reporting is to be recognized as beneficial for ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0477b2139e2703921d595af19df931
https://doi.org/10.2165/11594320-000000000-00000
https://doi.org/10.2165/11594320-000000000-00000
Autor:
Alexander N. O. Dodoo, Ambrose O. Isah, Sten Olsson, Shanthi N. Pal, Rachida Soulayami Bencheikh
Publikováno v:
Therapeutic Advances in Drug Safety. 3:25-34
The thalidomide tragedy in the late 1950s and early 1960s served as a wakeup call and raised questions about the safety of medicinal products. The developed countries rose to the challenge putting in place systems to ensure the safety of medicines. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bd4a99e2b7848874867136cdc152859
https://doi.org/10.1177/2042098611425695
https://doi.org/10.1177/2042098611425695
Publikováno v:
Expert review of clinical pharmacology. 8(4)
In the past 20 years, many low- and middle-income countries have created national pharmacovigilance (PV) systems and joined the WHO’s global PV network. However, very few of them have fully functional systems. Scientific evidence on the local burde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9700cc05288530996c588ee0f4185500
https://pubmed.ncbi.nlm.nih.gov/26041035
https://pubmed.ncbi.nlm.nih.gov/26041035
Autor:
Victoria Nambasa, Gordon Sematiko, Shanthi N. Pal, Helen Byomire Ndagije, Dan Kajungu, Sten Olsson, Huldah Nassali, Elizabeth Namagala
Publikováno v:
Drug Safety
Background Although the national HIV control programme in Uganda has a well-established system for monitoring disease progression and treatment outcomes, monitoring of adverse drug reactions (ADRs) is inadequate. In order to address under-reporting o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0ee29b2d58b5079340395554aeb389
https://pubmed.ncbi.nlm.nih.gov/25749663
https://pubmed.ncbi.nlm.nih.gov/25749663